Nelarabine: A novel purine antimetabolite antineoplastic agent

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 1887-1899

  Buie, Larry W ^a   Epstein, Stacy S ^b   Lindley, Celeste M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

ara G; ara GTP; Arranon; leukemia; lymphoma; nelarabine; purine nucleoside analogue

Indexed keywords

CLADRIBINE; FLUDARABINE; NELARABINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ARTICLE; ATAXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CONFUSION; CYTOTOXICITY; DIARRHEA; DIZZINESS; DRUG ANALYSIS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; FEVER; HUMAN; LYMPHOBLASTOMA; MALAISE; MULTIPLE CYCLE TREATMENT; MYOCLONUS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; SEIZURE; SENSORY NEUROPATHY; SOMNOLENCE; T LYMPHOCYTE; THROMBOCYTOPENIA; VERTIGO; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; DRUG RESISTANCE, NEOPLASM; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOMA, T-CELL; PURINE NUCLEOSIDES;

EID: 36749059519     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.002     Document Type: Article

References (35)

1. Pazdur R to Cutler ES. Approval letter for NDA 21-877. FDA Web site
2. Available at:. http://www.fda.gov/cder/foi/appletter/2005/021877/tr.pdf Accessed February 4, 2006
3. FDA Briefing Document. Arranon® (nelarabine) injection. FDA Web site
4. Available at:. http://www.fda.gov/ohrms/dockets/ac/OS/briefing/2005-4174B2_03_01-GSK-Arranon.pdf Accessed February 4, 2006
5. Berg S., Blaney S., Devidas M., et al., for the Children's Oncology Group. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J Clin Oncol 23 (2005) 3376-3382
6. DeAngelo D., Yu D., Dodge R., et al. A phase II study of 2-amino-9-β-D- arabinosyl-6methoxy-9H-purine (506U78) in patients with relapse or refractory T-lineage acute lymphoblastic leukemias (ALL) or lymphoblastic lymphoma (LBL): CALGB Study 19801. Blood 100 (2002) 742 Abstract
7. Center for Drug Evaluation and Research. Application no 21-877. Medical review(s). FDA Web site
8. Available at:. http://www.fda.gov/cder/foi/nda/2005/021877_sOOO_Arranon_Medr.pdf Accessed February 4, 2006
9. Gandhi V., Plunkett W., Rodriguez Jr. C., et al. Compound GWS06U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16 (1998) 3607-3615
10. In: Chabner B., and Longo D. (Eds). Cancer Chemotherapy and Biotherapy: Principles and Practice. 4th ed (2006), Lippincott Williams & Wilkins, Philadelphia, Pa 212-228
11. Kisor D., Plunkett W., Kurtzberg J., et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 18 (2000) 995-1003
12. Pui C., and Evans W. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178
13. Center For Drug Evaluation and Research. Application no 21-877. Chemistry review(s). FDA Web site
14. Available at:. http://www.fda.gov/cder/foi/nda/2005/021877_s000_Arranon_Chemr.pdf Accessed February 4, 2006
15. Lambe C., Averett D., Paff M., et al. 2-Amino-6-methoxypurine arabinoside: An agent for T-cell malignancies. Cancer Res 55 (1995) 3352-3356
16. Prus K., Averett D., and Zimmerman T. Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: Nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res 50 (1990) 1817-1821
17. Rodriguez Jr. C., Mitchell B., Ayres M., et al. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 62 (2002) 3100-3105
18. Ono K., Ohashi A., Yamamoto A., et al. Inhibitory effects of 9-beta-D-arabinofuranosylguanine 5'-triphosphate and 9-beta-D-arabinoFuranosyladenine 5'-triphosphate on DNA polymerases from murine cells and oncornavirus. Cancer Res 39 (1979) 4673-4680
19. Rodriguez Jr. C., Strellrecht C., and Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 102 (2003) 1842-1848
20. Gudas L., Ullman B., Cohen A., and Martin Jr. D. Deoxyguanosine toxicity in a mouse T lymphoma: Relationship to purine nucleoside phosphorylase-associated immune dysfunction. Cell 14 (1978) 531-538
21. Ullman B., and Martin Jr. D. Specific cytotoxicity of arabinosylguanine toward cultured T-lymphoblasts. J Clin Invest 74 (1984) 951-955
22. Verhoef V., and Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B- lymphoblasts. Cancer Res 45 (1985) 3646-3650
23. Shewach D., and Mitchell B. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells. Cancer Res 49 (1989) 6498-6502
24. Gandhi V., Plunkett W., Weller S., et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 19 (2001) 2142-2152
25. Center for Drug Evaluation and Research. Application no 21-877. Clinical pharmacology and biopharmaceutics review(s). FDA Web site
26. Available at:. http://www.fda.gov/cder/foi/nda/2005/021877_s000_Arranon_BioPharmr.pdf Accessed February 4, 2006
27. Weissmann J., Vollmer M., and Pribilla O. Survey of the distribution of adenosine deaminase and superoxide dismutase markers in different populations. Hum Hered 32 (1982) 344-356
28. Battistuzzi G., Ludicone P., Santolamazza P., and Petrucci R. Activity of adenosine deaminase allelic forms in intact erythrocytes and in lymphocytes. Ann Hum Genet 45 (1981) 15-19
29. Kurtzberg J., Ernst T., Keating M., et al. Phase I study of SO6U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23 (2005) 3396-3403
30. Thompson M., Pro B., Sarris A., et al. Results of a phase II study of 506U78 (nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma. Blood 106 (2005) 753a Abstract 2681
31. Goekbuget N., Arnold R., Atta J., et al. Compound GWS06U78 has high single-drug activity and good feasibility in heavily pretreated relapsed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) and offers the option for cure with stem cell transplantation (SCT). Blood 106 (2005) 47a Abstract 150
32. Czuczman M., Porcu P., Johnson J., et al., for Cancer and Leukemia Group B. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lympkoma 48 (2007) 97-103
33. Cohen M., Johnson J., Massie T., et al. Approval summary: Nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 12 (2006) 5329-5335
34. Combination chemotherapy in treating young people with newly diagnosed T-cell acute lymphoblastic leukemia
35. Available at:. http://www.clinicaltrials.gov/ct/show/NCTO0408005 Accessed April 23, 2007